CN1637018A - 二肽基肽酶iv的新效应物 - Google Patents

二肽基肽酶iv的新效应物 Download PDF

Info

Publication number
CN1637018A
CN1637018A CNA2004100833079A CN200410083307A CN1637018A CN 1637018 A CN1637018 A CN 1637018A CN A2004100833079 A CNA2004100833079 A CN A2004100833079A CN 200410083307 A CN200410083307 A CN 200410083307A CN 1637018 A CN1637018 A CN 1637018A
Authority
CN
China
Prior art keywords
salt
thiazolidine
acid
fumarate
dipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100833079A
Other languages
English (en)
Inventor
汉斯-乌尔里希·德穆特
康拉德·格隆德
达格玛·施伦齐希
苏珊·克鲁贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of CN1637018A publication Critical patent/CN1637018A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明提供由氨基酸及噻唑烷或吡咯烷基团形成的二肽模拟物，其中该氨基酸选自亮氨酸、谷氨酰胺、脯氨酸、天冬酰胺及天冬氨酸，以及它们的盐。本发明还提供包含这些二肽模拟物的药物组合物。

Description

二肽基肽酶IV的新效应物
本申请是1999年5月28日提交的，发明名称为“二肽基肽酶IV的新效应物”的中国专利申请99806723.7的分案申请。
技术领域
本发明涉及由一个氨基酸及一个噻唑烷或吡咯烷基团构成的二肽化合物及与二肽化合物类似的化合物，及其盐，下文中称为二肽化合物，也涉及该化合物在治疗哺乳动物葡萄糖耐受不良，糖尿，高脂血症，代谢性酸中毒，糖尿病，糖尿病性神经病和肾病及糖尿病后遗症中的应用。
因此，本发明也涉及在作为如下的酶的活性降低效应物(底物，伪底物，抑制剂，结合蛋白，抗体等等)的二肽化合物的辅助下降低哺乳动物血糖浓度的简便方法，所述的酶具有与二肽基肽酶IV相似或相同的酶活性。
背景技术
DP IV或DP IV类似物(例如胞液性DP II有与DP IV几乎相同的底物特异性)在血循环中具有活性，在血液循环中当脯氨酸或丙氨酸是N末端氨基酸相邻残基时，DP IV或DP IV类似物能够高特异性地从生物学活性肽N末端分解出二肽。
葡萄糖依赖型促胰岛多肽：肠抑胃肽1-2(GIP1-42)及类胰高血糖素肽酰胺-1 7-36(GLP-17-36)，即通过胰腺刺激葡萄糖诱导型胰岛素分泌的激素(也叫做肠降血糖素)，是DP IV的底物，因为后者在体外及体内能从这些肽的N末端序列上分别分解出酪氨酸—丙氨酸及组氨酸—丙氨酸二肽。
降低在体内分解这些底物的DP IV及类DP IV酶活性能够在实验室及哺乳动物病理条件下有效地抑制不希望的酶活性。例如，II型糖尿病(包括成人型糖尿病)是建立在胰岛素分泌减少或特别是来自蛋白水解的异常肠降血糖素浓度所致的受体功能紊乱的基础上。
依照现有技术，使用胰岛素(例如从牛胰岛分离或基因工程技术得到的物质)来治疗高糖血症及其相应的原因和后遗症(包括糖尿病)。所有已知的方法包括比较先进的手段都需要大量的物质，高额的费用并对患者的生活质量有明显的损害。传统方法(从十九世纪三十年代开始使用的每日静脉注射胰岛素)治疗该疾病的急性症状，但持续使用导致严重的血管变化(动脉硬化)及神经损伤。
最近有建议皮下埋置植入物(胰岛素以计量的方式被释放，不需要日常的注射)及植入(移植)完好的朗罕氏细胞到功能损伤的胰腺或其它器官及组织。这种移植要求有高水平技术。而且，它们涉及对受体生物体的手术介入，这可造成危险，甚至，在细胞移植时需要抑制或干扰免疫***。
作为DP IV及类DP IV酶活性抑制剂的丙氨酰吡咯烷及异亮氨酰噻唑烷的使用已从PCT/DE 97/00820知道，盐酸异亮氨酰吡咯烷及异亮氨酰噻唑烷的使用已从DD 296 075中知道。异亮氨酰噻唑烷，其在后一现有技术中被使用，是天然的，也就是说L-苏型-异亮氨酰噻唑烷，在该两篇说明书的优先权日和申请日时，仅该型，即异亮氨酰噻唑烷天然的形式。
已明确知道这些化合物特别是L-苏型-异亮氨酰噻唑烷是DP IV及类DP IV酶活性的良好效应物，但这些化合物的使用对一些患者及疾病会造成问题。
例如糖尿病时，依赖于症状及严重程度，需要使用与现有已知化合物不同的效应物：如已知为了以优化方式进行疾病的治疗，糖尿病患者的病情必须逐个稳定。在一些时候，例如通过DP IV效应物降低活性应该是足够的。也会出现高水平抑制剂活性及长期同样药物的使用所造成的副作用，特别在长期治疗中。而且，为了增加体内效应物的吸收率需改善某些转运特性。
发明内容
本发明的目的是对例如哺乳动物葡萄糖糖耐受不良，糖尿，高脂血症，代谢性酸中毒，糖尿病，糖尿病性神经病和肾病及糖尿病后遗症的治疗提供一种新的(特别是降低活性的)效应物，及治疗这些疾病的简单方法。
本发明的目的通过提供由一种氨基酸及一种噻唑烷或吡咯烷基团形成的二肽化合物或二肽类似物及其盐来达到。
将这些效应物给予哺乳动物，优选口腔给予时，内源性(或额外外源性给予)的促胰岛肽GIP1-42及GLP-17-36(或GLP-17-37或它的类似物)被DP IV或类DP IV酶分解而减少，因此这些肽激素或其类似物的浓度的降低被减慢或延迟。因此，本发明是建立在血液循环中起作用的DP IV或类DP IV酶活性的降低对血糖水平会造成影响这个发现的基础上。已发现：
1.DP IV或类DP IV酶活性的降低能提高葡萄糖刺激的或外来的肠降血糖素(或其类似物)的相对稳定性，也就是说通过给予DPIV或类DP IV蛋白的效应物，使对血中肠降血糖素分解的控制成为可能；
2.肠降血糖素(或其类似物)的生物学分解稳定性的提高导致内源性胰岛素作用的变化；
3.通过降低血液中DP IV或类DP IV酶活性而提高肠降血糖素的稳定性导致葡萄糖诱导性胰岛素作用的随后变化，因此导致对由DP IV效应物控制的血糖水平的调节。
对本发明的这一目的特别合适的是二肽化合物，其氨基酸选自天然氨基酸，例如亮氨酸，缬氨酸，谷氨酰胺，脯氨酸，异亮氨酸，天冬酰胺及天冬氨酸。
附图说明
图1是毛细管区带电泳(CE)分离异亮氨酰噻唑烷异构体的图，其显示L-苏型-Ile-Thia*延胡索酸盐、L-别-Ile-Thia*延胡索酸盐、D-苏型-Ile-Thia*延胡索酸盐、D-别-Ile-Thia*延胡索酸盐的1∶1∶1∶1的混合物的CE分离结果，方法和测量条件如下：
用来自Beckmann公司的“P/ACE***MDQ”进行CE研究
 物质     CE(min)
 L-threo-IT*F     160
 D-threo-IT*F     158
 L-allo-IT*F     154
 D-allo-IT*F     150
操作条件
缓冲液：20mM磷酸盐，pH 7.0，100mM β-羟基-丙基-环糊精
毛细管：50/60.2cm，25μm内径，用丙烯酰胺包被
电压：10kV
检测：在214nm用光电二极管阵列检测器检测
温度：7℃。
图2是Ile-Thia*延胡索酸盐的CE分离的图，其显示L-苏型-Ile-Thia*延胡索酸盐与D-别-Ile-Thia*延胡索酸盐的1∶1000的混合物的CE分离结果。
图3显示在口服给予各种H-Ile-Thia立体异构体(5μg/300g大鼠)后的血清DP IV活性。酶活性仅受L-别-Ile-Thia和L-苏型-Ile-Thia影响。
图4显示各种氨酰噻唑烷对大鼠葡萄糖耐受的作用(用2g/300gWistar大鼠在0时间点进行口服葡萄糖耐受试验，在口服葡萄糖刺激之前10分钟给予DP IV抑制剂)。
具体实施方式
在本发明中，通过口服给予高亲和性低分子量酶抑制剂相对于在治疗病理症状时广泛使用的外科技术是比较经济的选择。通过针对稳定性，转运及清除特性利用化学方法进行的设计，可调节作用模式及适应不同个体的特性。
如上所说，例如在糖尿病的长期治疗的情况下，可能必须提供具有所述活性的效应物，其可符合患者的不同要求及治疗他们的症状。本发明所说的二肽化合物显示出在(二肽化合物)浓度为10微摩尔，特别在表1所示的条件下，二肽基肽酶IV或类DP IV酶活性至少降低10％，特别是至少降低40％。通常也要求降低至少60％或70％。优选的效应物还可显示最多降低活性20％或30％。而且，本发明化合物的特别是通过转运Pep T1的转运特性显著改善。
特别优选的二肽化合物是L-别-异亮氨酰噻唑烷及其盐类。这些化合物与L-苏型-异亮氨酰噻唑烷相比，经转运肽Pep T1的转运改善高达5倍，同时对于葡萄糖调节具有大致相同的作用程度。
在表1进一步给出优选化合物。
本发明中二肽化合物的盐类可为，例如，有机盐如乙酸盐，琥珀酸盐，酒石酸盐或延胡索酸盐，或无机酸盐如磷酸盐或硫酸盐。最好使用延胡索酸盐，其在对水解作用有高度稳定性及比盐酸盐更不易溶解的同时，有很好的作用。从盖仑制剂的观点来说，这些特点也是有益的。
也优选L-苏型-异亮氨酰吡咯烷及其盐类，特别是延胡索酸盐，及L-别-异亮氨酰吡咯烷及其盐类，特别是延胡索酸盐。
二肽化合物的盐类可以二肽(二肽类似物)组分与盐类组分的摩尔比为1∶1或2∶1存在。例如，(异亮氨酰噻唑烷)2延胡索酸。
特别优选的盐类是L-苏型-异亮氨酰噻唑烷及L-别-异亮氨酰噻唑烷的延胡索酸盐类。
本发明涉及二肽基肽酶IV(DP IV)或类DP IV酶活性的效应物及它们在降低哺乳动物血清中的血糖浓度到高血糖症特征性血糖浓度以下中的应用。本发明特别涉及本发明所述的DP IV或类DP IV酶活性效应物在预防或减轻哺乳动物的病理代谢异常中的应用，所述病理代谢异常为例如，哺乳动物中的葡萄糖耐受不良，糖尿，高脂血症，代谢性酸中毒，糖尿病，糖尿病性神经病和肾病及糖尿病后遗症。在进一步优选的实施方案中，本发明涉及降低哺乳动物血清中的血糖浓度到高血糖症特征性血糖浓度以下的方法，其特征在于给予哺乳动物治疗有效量的本发明所述的至少一种DP IV或类DP IV酶活性效应物。
在进一步优选的实施方案中，本发明涉及药物组合物，也就是说药物，其包括至少一种本发明所述的化合物或其盐类，任选地与一种或多种药物可接受载体及/或溶剂混合。
药物组合物可以是，例如，肠道外或肠道配方的形式并可含有合适载体或它们可以是包括适宜口服给药相应载体的口服配方的形式。
此外，药物组合物可包括一种或多种具有低血糖作用的活性成分，其可以是已知的活性成分。
本发明中DP IV或类DP IV酶活性的效应物可用来降低哺乳生物血清中血糖水平到高血糖血症特征性血糖浓度下，或用来生产相应的药物。
本发明中使用的DP IV或类DP IV酶效应物可作为用来降低哺乳动物中DP IV或类DP IV蛋白浓度的抑制剂，底物，伪底物，DP IV表达抑制剂，结合蛋白或这些酶蛋白的抗体或这些不同物质组合的药物可接受配方或配方混合物。本发明的效应物可以是DP IV抑制剂如二肽衍生物或二肽模拟物L-别-异亮氨酰噻唑烷及在表1中提到的效应物及其延胡索酸盐。本发明的效应物能使患者及疾病的治疗依照各自的情况来调整，特别是可以控制个体中发生的不耐受，过敏及副作用。
化合物也显示出不同的时间有效性。医生根据患者的不同情况能采取不同的方法：一方面，他能精确地设置作用的起始速度，另一方面，可控制作用的持续时间，特别是作用的强度。
本发明的方法代表着降低哺乳动物血清中已升高的血糖浓度的一种新的方法。其简单，可经济开发及适应于治疗中使用，特别对建立在高于平均血糖阈值基础上的疾病，适用于哺乳动物，更适用于人类药物。
效应物可以通过药学制剂的形式被给药，该药学制剂包括与现有技术已知的传统载体相结合的活性成分。例如，它们可非肠道给药(如，静脉注射，以生理盐水的形式)或肠道给药(如，口服，与传统的载体如葡萄糖相结合)。
为了使血糖值正常化，依照它们的内源稳定性及生物利用率，效应物需要每天一次或多次给药。例如，人用剂量可在每天0.01毫克到30.0毫克的范围内，优选范围在每千克体重0.01毫克到10毫克的效应物。
已发现哺乳动物的血中二肽基肽酶IV或类DP IV酶效应物给药的直接结果是，由于其活性的暂时降低，内源的(或额外给予的外源的)促胰岛肽肠抑胃肽GIP1-42及胰高血糖素样肽酰胺-1 7-26(GLP-17-36)(或GLP-17-37或它的类似物)被DP IV或类DP IV酶分解而降低，因此这些肽激素或其类似物的浓度的降低被减慢或延迟。通过DP IV效应物的作用，(内源性或外源性)肠降血糖素或其类似物的稳定性增加，其结果是由于对胰腺内朗罕氏细胞的肠降血糖素受体的促胰岛刺激来说前者的量增加，改变了身体本身胰岛素的有效性，其能刺激被治疗机体碳水化合物的代谢。
结果，被治疗机体血清中的血糖水平降低到高血糖血症特征性血糖浓度以下，因此可预防或减轻代谢异常，如葡萄糖耐受不良，糖尿，高糖血症及严重的代谢酸中毒及糖尿病，它们是长期血液中血糖升高的临床症状。
在现有技术所知的口服有效抗糖尿病药中，如此有效的低分子量物质至今为止是未知的(除了双胍二甲双胍：分子量为130)。氨酰基噻唑烷的分子量在146(甘氨酰噻唑烷)，203(异亮氨酰噻唑烷)到275(色氨酰噻唑烷)的范围内变化。相比之下，磺酰脲(优降糖：494)，糖类(阿卡波糖：630)及噻唑烷二酮(pioglitazon：586)的分子量在500到700Da内变化。体内氨酰噻唑烷被氨基肽酶水解及酸水解形成内源性物质，例如氨基酸及半胱胺，因此本发明化合物作为口服抗糖尿病药的使用丰富了药品。
在小鼠及大鼠中，经口给予本发明中使用的化合物可比平均水平更好地治疗实验诱导的高糖血症(表2及3)。在对小鼠及大鼠所作的三周毒理学实验中，给予有效剂量的500到1000倍不能明显出现病理变化。
表1显示了本发明化合物对DP IV的有益作用。
表1：在30℃，pH 7.6及离子强度为0.125的条件下，不同效应物对于二肽基肽酶IV催化0.4毫摩尔底物H-Gly-Pro-pNA水解反应的作用
 效应物 效应物对DP IV的亲和性Ki[nM]  在10微摩尔效应物存在时DP IV的残余活性％
 二甲双胍 ＞＞1,000,000  100
 优降糖 ＞＞1,000,000  100
 阿卡波糖 ＞＞1,000,000  100
 H-天冬酰胺-吡咯烷 12,000  83.1
 H-天冬酰胺-噻唑烷 3,500  47.2
 H-天冬氨酸-吡咯烷 14,000  81.6
 H-天冬氨酸-噻唑烷 2,900  45.6
 H-天冬氨酸(NHOH)-吡咯烷 13,000  88.2
 H-天冬氨酸(NHOH)-噻唑烷 8,800  54.5
 H-谷氨酸-吡咯烷 2,200  38.5
 H-谷氨酸-酰噻唑烷 610  25.0
 H-谷氨酸(NHOH)-吡咯烷 2,800  44.9
 H-谷氨酸(NHOH)-噻唑烷 1,700  36.5
 H-组氨酸-吡咯烷 3,500  49.7
 H-组氨酸-噻唑烷 1,800  35.2
 H-脯氨酸-吡咯烷 4,100  50.2
 H-脯氨酸-噻唑烷 1,200  27.2
 H-异亮氨酸-吡咯烷 3,100  43.8
 H-异亮氨酸-噻唑烷 210  12.3
 H-L-别-异亮氨酸-噻唑烷 190  10.0
 H-缬氨酸-吡咯烷 480  23.3
 H-缬氨酸-噻唑烷 270  13.6
已知氨酰吡咯烷及氨酰噻唑烷可被小肠粘膜细胞，血清和肝细胞上的脯氨酸氨基肽酶及氨酰基脯氨酸二肽酶所分解，且噻唑烷环在酸存在时(如胃酸)趋于打开，形成相应的半胱胺衍生物(见US 458407)。因此，当口服给药时，惊奇地发现活性成分具有剂量依赖型有效性。可在下表中看到在对健康的Wistar大鼠经口给予L-别-异亮氨酸-噻唑烷后，L-别-异亮氨酸-噻唑烷对血清DP IV活性的剂量依赖作用。
表2：经口给予及依赖于L-别-异亮氨酸-噻唑烷的剂量后在30℃，pH 7.6及0.125的离子强度的条件下，血清中的DP IV对于0.4毫摩尔的底物H-甘氨酸-脯氨酸-pNA的残余活性，在给予抑制剂30分钟后检测
    每只试验动物的剂量     DP IV的残余活性％
    0毫克     100
    2.5毫克     52
    5.0毫克     40
    10毫克     28
    20毫克     29
在糖尿病动物模型中，经口给予本发明的活性成分L-别-异亮氨酸-噻唑烷并同步口服糖刺激物后，可达到惊奇也是希望看到的结果，就是其具有降糖作用(表3)。
为了加强各种抗糖尿病药的降血糖作用，通常是混合使用不同的口服有效抗糖尿病药。虽然本发明中效应物的抗糖尿病作用是不依赖其它已知口服抗糖尿病药，为了达到理想的正常血糖效果，本发明的活性成分类似地可以合适制剂的形式可适用于组合治疗。
因此，本发明中所使用的化合物可制成传统配方，例如，片剂，胶囊，糖丸，药丸，栓剂，小粒，气雾剂，糖浆，液体，固体及乳剂及悬浮液和溶液，使用惰性，非毒性，药物可接受的载体及添加剂或溶剂。在这样的配方中，每一例子中药物学有效化合物优选以总混合物的约0.1到80％(重量)、优选1-50％(重量)的浓度存在，也就是说足够产生指定范围的剂量的量。
表3：对同步进行糖耐受试验不同的动物模型大鼠经口给予20微摩尔的L-别-异亮氨酸-噻唑烷后，在60分钟期间循环血糖的降低程度
动物模型   对照组的糖浓度，以％表示   用L-别-异亮氨酸-噻唑烷治疗后的糖浓度，以％表示
Wistar大鼠，健康   100   82
Wistar大鼠(糖尿病2b-模型，肥胖)   100   73
胃肠道粘膜对本发明中所使用化合物的良好吸收使得能够使用大量盖仑制剂：
这些物质作为药物能以糖丸，胶囊，可咬型胶囊，片剂，滴剂，糖浆及栓剂和鼻腔喷雾的形式被使用。
通过使用溶剂及/或载体，任选地使用乳化剂及/或分散剂来扩散活性成分生产配方，任选地，例如水作为稀释剂时有机溶剂可作为助溶剂。
下列的辅助成分可提及：水，非毒性有机溶剂，如石蜡(矿物油部分)，植物油(如油菜籽油，花生油，芝麻油)，醇类(如乙醇，甘油)，乙二醇类(如丙二醇，聚乙二醇)；固体载体，例如粉碎的天然矿物质(高度分散的硅酸，硅酸盐)，糖类(如未加工糖，乳糖，葡萄糖)；乳化剂，如非离子及阴离子乳化剂(如聚氧乙烯脂肪酸酯，聚氧乙烯脂肪醇醚，烷基磺酸盐及芳基磺酸盐)，分散剂(如，木质素，亚硫酸废液，甲基纤维素，淀粉及聚乙烯吡咯酮)及助流剂(如硬脂酸镁，滑石，硬脂酸及十二烷基硫酸钠)及任选地调味剂。
传统的给药方式是有效的，优选肠道或肠道外给药，特别是经口给药。在肠道给药时，除了包括上述的载体，片剂也可包括其它添加剂，如柠檬酸钠，碳酸钙及磷酸钙，也可加入各种辅助成分，如淀粉，特别是土豆淀粉，明胶等。为制成片剂可使用助流剂，如硬脂酸镁，十二烷基硫酸钠，滑石。在为口服使用的水性悬浮液及/或酏剂的情况下，为了各种口味除了上述所提及的添加剂，可在有效成分中加入矫味剂或色素。
对于肠道外给药，可使用活性成分的溶液，其使用了合适的液态载体物质。在静脉给药时，已证明给药剂量大约在0.01到2.0克/千克体重/天的范围内，特别是在0.01到1.0克/千克体重/天的范围内效果较好，在肠道给药时，给药剂量大约在0.01到2.0克/千克体重/天的范围内，特别是在0.01到1.0克/千克体重/天的范围内效果较好。
不过在一些时候，根据试验动物或患者的体重或给药途径，并且以动物的种类及其对药物的个体或给药间隔的不同反应为基础，必须以不同于指示量给药。一些时候例如使用少于上面所提及的最小剂量就够了，而另一些时候需使用超过上述所提及剂量的上限。当使用较大剂量时，最好一天分成几份使用。对于人类也是上述的剂量范围，同时上面的建议也适用。
药物配方的实施例
1.每粒胶囊中含有100毫克的L-别-异亮氨酰噻唑烷：
对于约10,000粒胶囊，需准备下列成分的溶液：
L-别-异亮氨酰噻唑烷盐酸盐    1.0千克
甘油                         0.5千克
聚乙二醇                     3.0千克
水                           0.5千克
                             5.0千克
溶液以已知方式放入软明胶胶囊中，胶囊适于咀嚼或吞咽。
2.含有100毫克L-别-异亮氨酰噻唑烷的片剂/糖衣片剂或糖丸：
下面是关于制备100,000个片剂所需的量：
L-别-异亮氨酰噻唑烷盐酸盐，细碎      10.0千克
葡萄糖                               4.35千克
乳糖                                 4.35千克
淀粉                                 4.50千克
纤维素，细碎                         4.50千克
上述成分混合后与下面溶液相混，该溶液由以下来制备
聚乙烯吡咯烷酮      2.0千克
多乙氧基醚          0.1千克
及水                大约5.0千克
并用已知的方法将潮湿块磨碎成粒状，随后加入0.2千克的硬脂酸镁，干燥。最后得到30.0千克的片剂混合物，将其制成圆顶样每片300毫克的片剂。该片剂能用已知的方法包衣或糖衣化。
下面是优选化合物的技术数据。
关于Ile-Thia * 延胡索酸盐(异构体)及其它盐类的实验
物质 Ki  Mp(℃)  CE(min)  MS [α]H2O
L-苏型-IT*F 8*10-8  150DSC  160  203 -10.7(405nm)
D-苏型-IT*F 无抑制  147  158  203 没测
L-别-IT*F 2*10-7  145-6  154  203 -4.58(380nm)
D-别-IT*F 无抑制  144-6  150  203 4.5(380nm)
IT*F＝异亮氨酰噻唑烷延胡索酸盐
核磁共振及高效液相色谱数据证实了实验物质的性质。
测定物质Ki的测量条件
酶：在25毫摩尔Tris pH 7.6，30％硫酸铵，0.5毫摩尔EDTA，0.5毫摩尔DTE中的DP IV猪肾，0.75毫克/毫升，18单位/毫升(GPpNA)
储存溶液：用测量缓冲液稀释成1∶250
缓冲液：40毫摩尔HEPES pH 7.6，I＝0.125(KCl)
底物：GPpNA*HCl
储存溶液：2.1毫摩尔
测量装置：Perkin-Elmer生物分析读数仪，HTS 7000Plus，T＝30℃
           λ＝450纳米
测量混合物：100微升 缓冲液
100微升 底物(三种不同浓度0.8毫摩尔-0.2毫摩尔)50微升水/抑制剂(七种不同浓度，2.1微摩尔-32.8纳摩尔)
10微升 酶
缓冲液，水/抑制剂及酶预热到30℃，反应在加入如上一样预热的底物后开始。
检测进行四次。
测量时间为10分钟。
熔点测定
使用来自Leica Aktiengesellschaft的Kofler加热平台显微镜或DSC仪器(Heumann-Pharma)来测定熔点，数值未校正。
旋光性
用来自Perkin-Elmer公司的“Polarimeter 341”或更先进的设备记录在不同波长条件下的旋转值。
质谱测量条件
在购自PE Sciex公司的“API165”或“API 365”设备上利用电喷离子化(ESI)来记录质谱。
这个试验中浓度大约为c＝10微克/毫升，物质被MeOH/H2O50∶50，0.1％HCO2H吸收，使用电喷泵(20微升/分钟)灌输。在阳性状态[M+H]+，ESI电压U＝5600V的条件下测量。
盐类有以下数据：
IT*盐类 Ki  M(gmol-1)  Mp(℃)
琥珀酸盐 5.1e-8  522.73  116
酒石酸盐 8.3e-8  352.41  122
延胡索酸盐 8.3e-8  520.71  156
盐酸盐 7.2e-8  238.77  169
磷酸盐 1.3e-7  300.32  105
检测Ile-Thia的溶解度
Ile-Thia * 延胡索酸盐
称量为10.55毫克
相应于0.02毫摩尔(520.72克/摩尔)
加入100微升H2O蒸馏
100微升不溶，目视：对表面不湿润
从200微升开始溶解
一直到400微升才完全溶解
2.63％
因此说这种盐很少潮湿并不易分解
Ile-Thia * 琥珀酸盐
称量为16.6毫克
相应于0.031毫摩尔(522.73克/摩尔)
加入16微升H2O蒸馏
16微升不溶，目视：“吸收“水分
从66微升到1.5毫升可观察到物质不完全溶解
Ile-Thia * 酒石酸盐
称量为17.3毫克
相应于0.049毫摩尔(352.41克/摩尔)
加入100微升H2O蒸馏
100微升完全溶解
17.3％
Ile-Thia * 磷酸盐
称量为15.5毫克
相应于0.051毫摩尔(300.32克/摩尔)
加入100微升H2O蒸馏
可观察到100微升微溶
不断每次加入100微升水
到400微升时完全溶解
3.87％
Ile-Thia * 盐酸盐
称量为16.1毫克
相应于0.067毫摩尔(238.77克/摩尔)
加入100微升H2O蒸馏
100微升完全溶解
16.1％
Ile-Thia * 盐类的概括分析
Boc保护氨基酸Boc-Ile-OH放入乙酸乙酯中并将混合物冷却到大约零下5℃。逐滴加入N-甲基吗啉，在恒温下逐滴加入氯化新戊酸(试验室规模)或新己酰氯(中试规模)。为了活化，需将反应物搅拌几分钟。随后依次逐滴加入N-甲基吗啉(试验室规模)及噻唑烷盐酸盐(试验室规模)，加入噻唑烷(中试规模)。实验室中的加工是用传统方法使用盐溶液，中试时混合物用氢氧化钠及醋酸溶液来纯化。
使用盐酸/二恶烷(试验室规模)或硫酸(中试规模)来除去Boc保护基团。
在实验室中从乙醇/***中结晶出盐酸盐。
在中试中，通过加入氢氧化钠/氨来制备游离胺。延胡索酸溶解到热乙醇中，逐滴加入游离胺，出现(Ile-Thia)2延胡索酸盐的沉淀。
电泳分析异构体及对映体。

Claims (9)

1、由氨基酸及噻唑烷或吡咯烷基团形成的二肽模拟物，其中该氨基酸选自亮氨酸、谷氨酰胺、脯氨酸、天冬酰胺及天冬氨酸，以及它们的盐。
2、权利要求1所述的二肽模拟物，其中该氨基酸是谷氨酰胺。
3、权利要求1或2所述的二肽模拟物，其特征在于该盐是有机盐如乙酸盐、琥珀酸盐、酒石酸盐或延胡索酸盐，或无机酸盐如磷酸盐或硫酸盐。
4、权利要求3所述的二肽模拟物的盐，其特征在于它们以二肽组分与盐组分的摩尔比为1∶1或2∶1存在。
5、权利要求4所述的二肽模拟物的盐，其为延胡索酸盐。
6、药物组合物，其特征在于其包含至少一种权利要求1或2的化合物或其盐，任选地与一种或多种药学可接受的载体和/或溶剂组合。
7、药物组合物，其特征在于其包含至少一种权利要求3或4的化合物或其盐，任选地与一种或多种药学可接受的载体和/或溶剂组合。
8、权利要求5、6或7所述的药物组合物，其特征在于该载体是用于肠道外或肠道配方的载体。
9、权利要求6或7所述的药物组合物，其特征在于其以口服给药的配方存在。
CNA2004100833079A 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物 Pending CN1637018A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19823831.2 1998-05-28
DE19823831A DE19823831A1 (de) 1998-05-28 1998-05-28 Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB998067237A Division CN1332954C (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的效应物

Publications (1)

Publication Number Publication Date
CN1637018A true CN1637018A (zh) 2005-07-13

Family

ID=7869159

Family Applications (4)

Application Number Title Priority Date Filing Date
CNB998067237A Expired - Fee Related CN1332954C (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的效应物
CNA2004100833064A Pending CN1636593A (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物
CNA2004100833079A Pending CN1637018A (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物
CNA2007101369808A Pending CN101095675A (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNB998067237A Expired - Fee Related CN1332954C (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的效应物
CNA2004100833064A Pending CN1636593A (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101369808A Pending CN101095675A (zh) 1998-05-28 1999-05-28 二肽基肽酶iv的新效应物

Country Status (24)

Country Link
US (4) US6548481B1 (zh)
EP (6) EP1304327B1 (zh)
JP (1) JP2002516318A (zh)
KR (2) KR100630258B1 (zh)
CN (4) CN1332954C (zh)
AT (6) ATE336248T1 (zh)
AU (1) AU764262B2 (zh)
BR (1) BR9910758A (zh)
CA (1) CA2333603C (zh)
DE (10) DE19823831A1 (zh)
DK (2) DK1214936T3 (zh)
ES (5) ES2271458T3 (zh)
HK (3) HK1033316A1 (zh)
HU (1) HUP0102001A3 (zh)
IL (3) IL139862A0 (zh)
IS (3) IS5728A (zh)
NO (1) NO317989B1 (zh)
NZ (2) NZ508260A (zh)
PL (1) PL344403A1 (zh)
PT (2) PT1214936E (zh)
RU (3) RU2309161C2 (zh)
SI (2) SI1082314T1 (zh)
UA (1) UA54599C2 (zh)
WO (1) WO1999061431A1 (zh)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
CN1163594C (zh) * 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
US20080076811A1 (en) * 2000-01-21 2008-03-27 Bork Balkan Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
DE60124861T2 (de) * 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
JP2003523396A (ja) * 2000-02-25 2003-08-05 ノボ ノルディスク アクティーゼルスカブ ベータ細胞変性の抑制
JP2003528135A (ja) † 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
JP4101053B2 (ja) * 2000-08-10 2008-06-11 田辺三菱製薬株式会社 プロリン誘導体及びその医薬用途
EP1891948A1 (en) 2000-10-27 2008-02-27 Probiodrug AG Treatment of neurological and neuropsychological disorders
WO2002034242A2 (en) * 2000-10-27 2002-05-02 Probiodrug Ag Method for the treatment of neurological and neuropsychological disorders
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20070293426A1 (en) * 2001-04-02 2007-12-20 Hans-Ulrich Demuth Methods for improving islet signaling in diabetes mellitus and for its prevention
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US6944925B2 (en) * 2001-06-13 2005-09-20 Ttx Company Articulated connector reconditioning process and apparatuses
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
CN1321682C (zh) * 2001-06-27 2007-06-20 前体生物药物股份有限公司 新的二肽基肽酶iv抑制剂和它们作为抗癌药的用途
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003015768A2 (en) * 2001-08-16 2003-02-27 Probiodrug Ag Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
WO2003024942A1 (fr) 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Derive thiazolidine et son utilisation medicamenteuse
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
IL160917A0 (en) 2001-10-18 2004-08-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GB0125446D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
EP1695970A1 (en) * 2002-02-28 2006-08-30 Prosidion Limited Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis
KR20040095241A (ko) 2002-02-28 2004-11-12 프로시디온 리미티드 글루타미닐계 ｄｐｉｖ 억제제
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
EP1528931B1 (en) * 2002-08-09 2008-05-07 Prosidion Ltd. Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
ATE461212T1 (de) * 2002-09-18 2010-04-15 Prosidion Ltd Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
CA2524009C (en) 2003-05-05 2014-04-29 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602004010206T2 (de) 2003-08-13 2008-10-09 Takeda Pharmaceutical Co. Ltd. Dipeptidyl Peptidase Inhibitoren.
JP2007502991A (ja) 2003-08-20 2007-02-15 バイオサイト インコーポレイテッド 生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
WO2005020983A2 (en) * 2003-09-02 2005-03-10 Prosidion Ltd. Combination therapy for glycaemic control
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005039548A2 (en) 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR20150028829A (ko) 2003-11-17 2015-03-16 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101146849B1 (ko) 2003-12-11 2012-05-16 미쓰비시 타나베 파마 코퍼레이션 α-아미노산 유도체 및 그 의약 용도
WO2005058894A1 (en) * 2003-12-19 2005-06-30 Altana Pharma Ag Intermediates for the preparation of tricyclic dihydropyrano -imidazo -pyridines derivatives
CN101262851A (zh) * 2004-01-20 2008-09-10 诺瓦提斯公司 直接压片配方和方法
BRPI0507007A (pt) * 2004-01-20 2007-06-05 Novartis Ag formulação e processo de compressão direta
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
CA2559302C (en) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1794120B1 (en) * 2004-07-23 2012-04-11 Nuada, LLC Peptidase inhibitors
EP1782832A4 (en) * 2004-08-26 2009-08-26 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF DIABETES
PE20060652A1 (es) 2004-08-27 2006-08-11 Novartis Ag Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US8003790B2 (en) 2005-02-18 2011-08-23 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006133160A2 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AU2006278039B2 (en) * 2005-08-11 2010-10-21 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a DPP-lV inhibitor
PT1942898E (pt) * 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
JP5122462B2 (ja) 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
EP1971614A1 (en) 2005-11-14 2008-09-24 Probiodrug AG Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DK1971862T3 (da) 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
CA2649209A1 (en) 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
CA2649842C (en) 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR20090047546A (ko) 2006-09-07 2009-05-12 니코메드 게엠베하 당뇨병을 위한 조합 치료
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101652147B (zh) 2007-04-03 2013-07-24 田边三菱制药株式会社 二肽基肽酶iv抑制化合物和甜味剂的并用
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8604245B2 (en) 2007-06-04 2013-12-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2010534722A (ja) * 2007-07-27 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼ活性化薬およびその使用方法
EP2190434B1 (en) * 2007-08-17 2019-04-17 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP5906086B2 (ja) * 2008-08-15 2016-04-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患の治療に用いるためのプリン誘導体
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
AU2010319377B2 (en) 2009-11-13 2014-10-23 Astrazeneca Ab Immediate release tablet formulations
CA2780939C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Bilayer tablet formulations
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
MX2013008372A (es) 2011-02-01 2013-08-12 Astrazeneca Uk Ltd Formulaciones farmaceuticas que incluyen compuesto de amina.
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2532506A1 (de) 2011-06-06 2012-12-12 Battenfeld-Cincinnati Germany GmbH Abzugsvorrichtung für einen Extruder
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
DK3489226T3 (da) 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CA2928725A1 (en) 2013-11-05 2015-05-14 Esther Priel Compounds for the treatment of diabetes and disease complications arising from same
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JP2018123065A (ja) * 2017-01-30 2018-08-09 株式会社明治 インスリン分泌促進用組成物
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
SG11202102498UA (en) 2018-09-26 2021-04-29 Lexicon Pharmaceuticals Inc Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25023A (en) * 1859-08-09 Improved device for making electro-magnetic currents, constant or intermittent
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3879541A (en) 1970-03-03 1975-04-22 Bayer Ag Antihyperglycemic methods and compositions
US3960949A (en) 1971-04-02 1976-06-01 Schering Aktiengesellschaft 1,2-Biguanides
JPS4940442B2 (zh) * 1971-08-30 1974-11-02
CH602612A5 (zh) 1974-10-11 1978-07-31 Hoffmann La Roche
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
DD296075A5 (de) * 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
JP3262329B2 (ja) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
JPH05508624A (ja) 1990-04-14 1993-12-02 ニュー　イングランド　メデカル　センター　ホスピタルズ　インク ジペプチジル―アミノベプチダーゼ・４型の阻害剤
WO1991017767A1 (en) 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
JPH0819154B2 (ja) 1991-03-14 1996-02-28 江崎グリコ株式会社 ジペプチジルカルボキシペプチダーゼを阻害するペプチド
JPH04334357A (ja) * 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
ES2153831T3 (es) 1991-10-22 2001-03-16 New England Medical Center Inc Inhibidores de dipeptidil-aminopeptidasa de tipo iv.
DE4140177C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Nanosol-Akutform für Glibenclamid
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
CZ389398A3 (cs) 1996-05-29 1999-07-14 Prototek, Inc. Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
JPH10182687A (ja) * 1996-10-21 1998-07-07 Bayer Yakuhin Kk アカルボースの貯蔵安定化法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AR016751A1 (es) 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
AU4854999A (en) 1998-07-02 2000-01-24 Invitro Diagnostics, Inc. Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
DE19834591A1 (de) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000053171A1 (en) 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) * 1999-06-24 2001-01-09 Novartis Ag Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US7064145B2 (en) * 2000-02-25 2006-06-20 Novo Nordisk A/S Inhibition of beta cell degeneration
JP2003523396A (ja) 2000-02-25 2003-08-05 ノボ ノルディスク アクティーゼルスカブ ベータ細胞変性の抑制
JP2003528135A (ja) * 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
KR20040095241A (ko) * 2002-02-28 2004-11-12 프로시디온 리미티드 글루타미닐계 ｄｐｉｖ 억제제

Also Published As

Publication number Publication date
ES2271458T3 (es) 2007-04-16
HUP0102001A2 (hu) 2001-11-28
US6548481B1 (en) 2003-04-15
NZ508260A (en) 2003-06-30
PL344403A1 (en) 2001-11-05
ATE272059T1 (de) 2004-08-15
RU2003121766A (ru) 2005-02-10
HK1033316A1 (en) 2001-08-24
IS7764A (is) 2005-03-21
BR9910758A (pt) 2001-02-13
DE59904100D1 (de) 2003-02-27
WO1999061431A1 (de) 1999-12-02
DE19823831A1 (de) 1999-12-02
ES2193709T3 (es) 2003-11-01
EP1398030B1 (de) 2006-09-06
EP1215207A3 (de) 2002-07-03
IS2089B (is) 2006-03-15
EP1214936A3 (de) 2002-07-03
NZ525799A (en) 2004-09-24
CA2333603C (en) 2007-07-31
EP1304327B1 (de) 2005-02-23
EP1214936A2 (de) 2002-06-19
EP1304327A3 (de) 2003-05-02
CN1636593A (zh) 2005-07-13
HK1052708B (zh) 2005-05-27
EP1428533A3 (de) 2004-06-23
EP1082314B1 (de) 2003-04-23
EP1215207B1 (de) 2004-07-28
CN1303381A (zh) 2001-07-11
DE59910084D1 (de) 2004-09-02
US20080182798A1 (en) 2008-07-31
EP1214936B1 (de) 2004-07-28
KR100628668B1 (ko) 2006-09-27
SI1082314T1 (en) 2003-08-31
IS5728A (is) 2000-11-24
DE59913840D1 (de) 2006-10-19
HUP0102001A3 (en) 2001-12-28
RU2004101292A (ru) 2005-06-20
IS2130B (is) 2006-07-14
CN101095675A (zh) 2008-01-02
ATE289598T1 (de) 2005-03-15
EP1082314A1 (de) 2001-03-14
HK1047887A1 (en) 2003-03-14
KR20010071335A (ko) 2001-07-28
DE59913784D1 (de) 2006-09-28
DK1214936T3 (da) 2004-12-06
NO20005994D0 (no) 2000-11-27
EP1398030A3 (de) 2004-04-07
ES2271723T3 (es) 2007-04-16
HK1052708A1 (en) 2003-09-26
EP1398030A2 (de) 2004-03-17
EP1304327A2 (de) 2003-04-23
HK1047887B (zh) 2005-05-13
UA54599C2 (uk) 2003-03-17
NO317989B1 (no) 2005-01-17
JP2002516318A (ja) 2002-06-04
KR20040063979A (ko) 2004-07-15
RU2309161C2 (ru) 2007-10-27
EP1428533A2 (de) 2004-06-16
DE59910083D1 (de) 2004-09-02
ES2223981T3 (es) 2005-03-01
SI1304327T1 (zh) 2005-08-31
DK1304327T3 (da) 2005-06-27
IL139862A (en) 2006-08-20
IL139862A0 (en) 2002-02-10
CN1332954C (zh) 2007-08-22
DE29909210U1 (de) 1999-09-09
ATE231497T1 (de) 2003-02-15
ATE271869T1 (de) 2004-08-15
ATE336248T1 (de) 2006-09-15
IS7763A (is) 2005-03-21
DE29909208U1 (de) 1999-09-09
US20050203030A1 (en) 2005-09-15
IL175407A0 (en) 2006-09-05
EP1215207A2 (de) 2002-06-19
EP1428533B1 (de) 2006-08-16
AU764262B2 (en) 2003-08-14
RU2227800C2 (ru) 2004-04-27
ES2238641T3 (es) 2005-09-01
KR100630258B1 (ko) 2006-10-02
PT1214936E (pt) 2004-12-31
DE29909211U1 (de) 1999-09-23
PT1304327E (pt) 2005-07-29
US20030134802A1 (en) 2003-07-17
NO20005994L (no) 2001-01-25
ATE338546T1 (de) 2006-09-15
CA2333603A1 (en) 1999-12-02
AU4370999A (en) 1999-12-13
DE59911670D1 (de) 2005-03-31

Similar Documents

Publication Publication Date Title
CN1637018A (zh) 二肽基肽酶iv的新效应物
CN100345866C (zh) 不稳定的dp iv抑制剂的化合物
CN1176915C (zh) 炔基苯基芳香杂环的菊糖激酶激活剂
EP1385508B1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN1089584C (zh) 动脉硬化和黄瘤的治疗
CN1053230A (zh) 新的聚4-氨基-2-羟基-1-甲基化合物脲基衍生物的制备方法
CN1622941A (zh) 基于谷氨酰胺酰基的dpiv抑制剂
CN1216545A (zh) 法呢基转移酶抑制剂
CN1976691A (zh) 半胱胺用于治疗高胆固醇血症和糖尿病并发症
CN1385421A (zh) 新的α－氨基酸化合物、其制备方法和包含它们的药物组合物
CN1639164A (zh) 含氮杂环化合物
CN1950359A (zh) 作为IkB激酶抑制剂的基本纯净的2－{ [2－(2－甲基氨基－嘧啶－4－基)－1H－吲哚－5－羰基]－氨基}－3－(苯基吡啶－2－基－氨基)－丙酸
JP2010518097A (ja) チャネル活性化プロテアーゼ阻害剤としての化合物および組成物
CN1168711C (zh) 可逆含水pH敏感脂化试剂、组合物和应用的方法
CN1028528C (zh) 旋光活性4-羟基-8-(3-低烷氧基-4-苯基亚磺酰基苯基)吡唑并[1，5-α]-1，3，5-三嗪或其盐的制法
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
CN1202106A (zh) 选择性的β3肾上腺素能激动剂
RU2528233C2 (ru) СОЛИ МЕТИЛ(R)-7-[3-АМИНО-4-(2,4,5-ТРИФТОРФЕНИЛ)-БУТИРИЛ]-3-ТРИФТОРМЕТИЛ-5,6,7,8-ТЕТРАГИДРО-ИМИДАЗО[1,5-a]ПИРАЗИН-1-КАРБОКСИЛАТА
CN1615154A (zh) 干扰素tau的口服给药
CN1533277A (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CN1104209A (zh) 2，4-二氨基-3-羟基羧酸衍生物
CN1046853C (zh) 制备药用组合物的方法
AU2003262286A2 (en) Novel Effectors of Dipeptidyl Peptidase IV
CN1131035C (zh) 治疗识别机能障碍的方法
AU2006202684A1 (en) Novel effectors of dipeptidyl peptidase IV

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication